Identification O
of O
APC2 O
, O
a O
homologue O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
. O

The O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
- O
suppressor O
protein O
controls O
the O
Wnt O
signalling O
pathway O
by O
forming O
a O
complex O
with O
glycogen O
synthase O
kinase O
3beta O
( O
GSK O
- O
3beta O
) O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

Complex O
formation O
induces O
the O
rapid O
degradation O
of O
betacatenin O
. O

In O
colon B-Disease
carcinoma I-Disease
cells O
, O
loss O
of O
APC O
leads O
to O
the O
accumulation O
of O
betacatenin O
in O
the O
nucleus O
, O
where O
it O
binds O
to O
and O
activates O
the O
Tcf O
- O
4 O
transcription O
factor O
( O
reviewed O
in O
[ O
1 O
] O
[ O
2 O
] O
) O
. O

Here O
, O
we O
report O
the O
identification O
and O
genomic O
structure O
of O
APC O
homologues O
. O

Mammalian O
APC2 O
, O
which O
closely O
resembles O
APC O
in O
overall O
domain O
structure O
, O
was O
functionally O
analyzed O
and O
shown O
to O
contain O
two O
SAMP O
domains O
, O
both O
of O
which O
are O
required O
for O
binding O
to O
conductin O
. O

Like O
APC O
, O
APC2 O
regulates O
the O
formation O
of O
active O
betacatenin O
- O
Tcf O
complexes O
, O
as O
demonstrated O
using O
transient O
transcriptional O
activation O
assays O
in O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
. O

Human O
APC2 O
maps O
to O
chromosome O
19p13 O
. O

3 O
. O

APC O
and O
APC2 O
may O
therefore O
have O
comparable O
functions O
in O
development O
and O
cancer B-Disease
. O

A O
common O
MSH2 O
mutation O
in O
English O
and O
North O
American O
HNPCC B-Disease
families O
: O
origin O
, O
phenotypic O
expression O
, O
and O
sex O
specific O
differences O
in O
colorectal B-Disease
cancer I-Disease
. O

The O
frequency O
, O
origin O
, O
and O
phenotypic O
expression O
of O
a O
germline O
MSH2 O
gene O
mutation O
previously O
identified O
in O
seven O
kindreds O
with O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
was O
investigated O
. O

The O
mutation O
( O
A O
- O
- O
> O
T O
at O
nt943 O
+ O
3 O
) O
disrupts O
the O
3 O
splice O
site O
of O
exon O
5 O
leading O
to O
the O
deletion O
of O
this O
exon O
from O
MSH2 O
mRNA O
and O
represents O
the O
only O
frequent O
MSH2 O
mutation O
so O
far O
reported O
. O

Although O
this O
mutation O
was O
initially O
detected O
in O
four O
of O
33 O
colorectal B-Disease
cancer I-Disease
families O
analysed O
from O
eastern O
England O
, O
more O
extensive O
analysis O
has O
reduced O
the O
frequency O
to O
four O
of O
52 O
( O
8 O
% O
) O
English O
HNPCC B-Disease
kindreds O
analysed O
. O

In O
contrast O
, O
the O
MSH2 O
mutation O
was O
identified O
in O
10 O
of O
20 O
( O
50 O
% O
) O
separately O
identified O
colorectal B-Disease
families O
from O
Newfoundland O
. O

To O
investigate O
the O
origin O
of O
this O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
from O
England O
( O
n O
= O
4 O
) O
, O
Newfoundland O
( O
n O
= O
10 O
) O
, O
and O
the O
United O
States O
( O
n O
= O
3 O
) O
, O
haplotype O
analysis O
using O
microsatellite O
markers O
linked O
to O
MSH2 O
was O
performed O
. O

Within O
the O
English O
and O
US O
families O
there O
was O
little O
evidence O
for O
a O
recent O
common O
origin O
of O
the O
MSH2 O
splice O
site O
mutation O
in O
most O
families O
. O

In O
contrast O
, O
a O
common O
haplotype O
was O
identified O
at O
the O
two O
flanking O
markers O
( O
CA5 O
and O
D2S288 O
) O
in O
eight O
of O
the O
Newfoundland O
families O
. O

These O
findings O
suggested O
a O
founder O
effect O
within O
Newfoundland O
similar O
to O
that O
reported O
by O
others O
for O
two O
MLH1 O
mutations O
in O
Finnish O
HNPCC B-Disease
families O
. O

We O
calculated O
age O
related O
risks O
of O
all O
, O
colorectal B-Disease
, I-Disease
endometrial I-Disease
, I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
in O
nt943 O
+ O
3 O
A O
- O
- O
> O
T O
MSH2 O
mutation O
carriers O
( O
n O
= O
76 O
) O
for O
all O
patients O
and O
for O
men O
and O
women O
separately O
. O

For O
both O
sexes O
combined O
, O
the O
penetrances O
at O
age O
60 O
years O
for O
all O
cancers B-Disease
and O
for O
colorectal B-Disease
cancer I-Disease
were O
0 O
. O

86 O
and O
0 O
. O

57 O
, O
respectively O
. O

The O
risk O
of O
colorectal B-Disease
cancer I-Disease
was O
significantly O
higher O
( O
p O
< O
0 O
. O
01 O
) O
in O
males O
than O
females O
( O
0 O
. O
63 O
v O
0 O
. O
30 O
and O
0 O
. O
84 O
v O
0 O
. O
44 O
at O
ages O
50 O
and O
60 O
years O
, O
respectively O
) O
. O

For O
females O
there O
was O
a O
high O
risk O
of O
endometrial B-Disease
cancer I-Disease
( O
0 O
. O
5 O
at O
age O
60 O
years O
) O
and O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
( O
0 O
. O
2 O
at O
50 O
years O
) O
. O

These O
intersex O
differences O
in O
colorectal B-Disease
cancer I-Disease
risks O
have O
implications O
for O
screening O
programmes O
and O
for O
attempts O
to O
identify O
colorectal B-Disease
cancer I-Disease
susceptibility O
modifiers O
. O

Age O
of O
onset O
in O
Huntington B-Disease
disease I-Disease
: O
sex O
specific O
influence O
of O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
. O

Age O
of O
onset O
( O
AO O
) O
of O
Huntington B-Disease
disease I-Disease
( O
HD B-Disease
) O
is O
known O
to O
be O
correlated O
with O
the O
length O
of O
an O
expanded O
CAG O
repeat O
in O
the O
HD B-Disease
gene O
. O

Apolipoprotein O
E O
( O
APOE O
) O
genotype O
, O
in O
turn O
, O
is O
known O
to O
influence O
AO O
in O
Alzheimer B-Disease
disease I-Disease
, O
rendering O
the O
APOE O
gene O
a O
likely O
candidate O
to O
affect O
AO O
in O
other O
neurological B-Disease
diseases I-Disease
too O
. O

We O
therefore O
determined O
APOE O
genotype O
and O
normal O
CAG O
repeat O
length O
in O
the O
HD B-Disease
gene O
for O
138 O
HD B-Disease
patients O
who O
were O
previously O
analysed O
with O
respect O
to O
CAG O
repeat O
length O
. O

APC2 O
, O
a O
homologue O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
, O
was O
identified O
. O

The O
study O
identified O
APC2 O
, O
which O
is O
homologous O
to O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
. O

Researchers O
reported O
the O
identification O
of O
APC2 O
, O
structurally O
related O
to O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
. O

APC2 O
, O
a O
protein O
homologous O
to O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
, O
has O
been O
identified O
. O

The O
identification O
of O
APC2 O
revealed O
its O
homology O
to O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
. O

The O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
suppressor O
regulates O
Wnt O
signalling O
through O
complex O
formation O
with O
GSK O
- O
3beta O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

The O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
suppressor O
modulates O
Wnt O
signalling O
by O
assembling O
a O
complex O
containing O
GSK O
- O
3beta O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

Through O
its O
association O
with O
GSK O
- O
3beta O
, O
axin O
/ O
conductin O
and O
betacatenin O
, O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
suppressor O
influences O
Wnt O
pathway O
activity O
. O

Complex O
formation O
with O
GSK O
- O
3beta O
, O
axin O
/ O
conductin O
and O
betacatenin O
enables O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
suppressor O
to O
regulate O
the O
Wnt O
pathway O
. O

The O
Wnt O
signalling O
cascade O
is O
governed O
by O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
APC I-Disease
) I-Disease
tumour I-Disease
suppressor O
through O
its O
interactions O
with O
GSK O
- O
3beta O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

In O
colon B-Disease
carcinoma I-Disease
cells O
, O
APC O
loss O
results O
in O
nuclear O
accumulation O
of O
betacatenin O
, O
which O
activates O
the O
Tcf O
- O
4 O
transcription O
factor O
. O

APC O
deficiency O
in O
colon B-Disease
carcinoma I-Disease
cells O
leads O
to O
the O
build-up O
of O
nuclear O
betacatenin O
and O
subsequent O
activation O
of O
Tcf O
- O
4 O
. O

Within O
colon B-Disease
carcinoma I-Disease
cells O
, O
APC O
loss O
promotes O
nuclear O
betacatenin O
accumulation O
that O
triggers O
Tcf O
- O
4 O
activation O
. O

APC O
loss O
in O
colon B-Disease
carcinoma I-Disease
selectively O
enhances O
nuclear O
betacatenin O
levels O
, O
enabling O
activation O
of O
Tcf O
- O
4 O
. O

Colon B-Disease
carcinoma I-Disease
cells O
lacking O
APC O
show O
nuclear O
accumulation O
of O
betacatenin O
that O
binds O
and O
activates O
Tcf O
- O
4 O
. O

Similar O
to O
APC O
, O
APC2 O
modulates O
active O
betacatenin O
- O
Tcf O
complex O
formation O
, O
as O
shown O
in O
transcriptional O
assays O
using O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
. O

APC2 O
, O
like O
APC O
, O
influences O
the O
generation O
of O
active O
betacatenin O
- O
Tcf O
complexes O
according O
to O
studies O
in O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
. O

Functional O
assays O
using O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
reveal O
that O
APC2 O
also O
regulates O
active O
betacatenin O
- O
Tcf O
complex O
formation O
. O

In O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
, O
APC2 O
was O
shown O
to O
modulate O
the O
assembly O
of O
active O
betacatenin O
- O
Tcf O
complexes O
. O

Studies O
in O
APC O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
demonstrate O
that O
APC2 O
participates O
in O
regulating O
betacatenin O
- O
Tcf O
complex O
activation O
. O

APC O
and O
APC2 O
may O
share O
similar O
functional O
roles O
in O
cancer B-Disease
and O
development O
. O

The O
findings O
suggest O
that O
APC O
and O
APC2 O
perform O
analogous O
functions O
in O
both O
development O
and O
cancer B-Disease
. O

APC O
and O
APC2 O
appear O
to O
exhibit O
overlapping O
functional O
roles O
in O
developmental O
processes O
and O
cancer B-Disease
. O

It O
is O
likely O
that O
APC O
and O
APC2 O
have O
functionally O
comparable O
roles O
in O
development O
as O
well O
as O
cancer B-Disease
. O

These O
observations O
imply O
that O
APC O
and O
APC2 O
fulfil O
similar O
biological O
roles O
in O
cancer B-Disease
and O
developmental O
pathways O
. O

A O
recurrent O
MSH2 O
mutation O
found O
in O
English O
and O
North O
American O
HNPCC B-Disease
families O
shows O
distinct O
origins O
, O
phenotypic O
effects O
and O
sex O
- O
specific O
patterns O
in O
colorectal B-Disease
cancer I-Disease
. O

A O
shared O
MSH2 O
mutation O
in O
English O
and O
North O
American O
HNPCC B-Disease
families O
was O
examined O
with O
respect O
to O
its O
origin O
, O
phenotype O
and O
sex O
- O
related O
differences O
in O
colorectal B-Disease
cancer I-Disease
. O

This O
study O
investigates O
a O
common O
MSH2 O
mutation O
in O
HNPCC B-Disease
families O
from O
England O
and O
North O
America O
and O
its O
relationship O
to O
colorectal B-Disease
cancer I-Disease
, O
including O
sex O
- O
specific O
variation O
. O

A O
prevalent O
MSH2 O
mutation O
in O
HNPCC B-Disease
families O
from O
England O
and O
North O
America O
was O
analysed O
for O
its O
origins O
and O
for O
sex O
- O
specific O
colorectal B-Disease
cancer I-Disease
outcomes O
. O

The O
study O
characterises O
a O
recurring O
MSH2 O
mutation O
in O
English O
and O
North O
American O
HNPCC B-Disease
families O
and O
its O
impact O
on O
colorectal B-Disease
cancer I-Disease
, O
including O
sex O
- O
dependent O
differences O
. O

The O
frequency O
and O
origin O
of O
a O
germline O
MSH2 O
mutation O
in O
families O
with O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
were O
analysed O
alongside O
its O
phenotypic O
effects O
. O

This O
study O
examined O
the O
frequency O
and O
origins O
of O
a O
germline O
MSH2 O
mutation O
in O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
families O
and O
its O
phenotypic O
characteristics O
. O

Researchers O
investigated O
the O
prevalence O
and O
origins O
of O
a O
germline O
MSH2 O
mutation O
in O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
families O
, O
as O
well O
as O
its O
phenotype O
. O

An O
analysis O
was O
performed O
on O
the O
frequency O
, O
origin O
and O
phenotypic O
expression O
of O
a O
germline O
MSH2 O
mutation O
in O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
kindreds O
. O

This O
investigation O
focused O
on O
a O
germline O
MSH2 O
mutation O
in O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
HNPCC B-Disease
) O
families O
, O
analysing O
its O
frequency O
, O
source O
and O
phenotypic O
effects O
. O

Although O
initially O
observed O
in O
four O
of O
33 O
colorectal B-Disease
cancer I-Disease
families O
from O
eastern O
England O
, O
further O
screening O
reduced O
its O
frequency O
to O
four O
of O
52 O
English O
HNPCC B-Disease
kindreds O
. O

Expanded O
analysis O
showed O
that O
a O
mutation O
first O
detected O
in O
four O
of O
33 O
colorectal B-Disease
cancer I-Disease
families O
was O
ultimately O
confirmed O
in O
only O
four O
of O
52 O
English O
HNPCC B-Disease
kindreds O
. O

A O
mutation O
initially O
reported O
in O
several O
colorectal B-Disease
cancer I-Disease
families O
from O
eastern O
England O
was O
later O
verified O
in O
four O
of O
52 O
English O
HNPCC B-Disease
families O
. O

The O
mutation O
was O
first O
identified O
in O
four O
colorectal B-Disease
cancer I-Disease
families O
, O
but O
extended O
testing O
showed O
it O
to O
occur O
in O
only O
four O
of O
52 O
English O
HNPCC B-Disease
families O
. O

Initial O
findings O
of O
the O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
were O
refined O
after O
broader O
analysis O
confirmed O
its O
presence O
in O
four O
of O
52 O
English O
HNPCC B-Disease
kindreds O
. O

In O
contrast O
, O
the O
MSH2 O
mutation O
occurred O
in O
10 O
of O
20 O
colorectal B-Disease
families O
in O
Newfoundland O
. O

The O
MSH2 O
mutation O
was O
found O
at O
a O
higher O
frequency O
, O
appearing O
in O
10 O
of O
20 O
colorectal B-Disease
families O
from O
Newfoundland O
. O

Newfoundland O
colorectal B-Disease
families O
exhibited O
a O
50 O
% O
detection O
rate O
for O
the O
MSH2 O
mutation O
. O

Among O
Newfoundland O
colorectal B-Disease
families O
, O
the O
MSH2 O
mutation O
was O
detected O
in O
half O
of O
those O
examined O
. O

The O
study O
reported O
that O
10 O
out O
of O
20 O
colorectal B-Disease
families O
from O
Newfoundland O
carried O
the O
MSH2 O
mutation O
. O

Haplotype O
analysis O
using O
microsatellite O
markers O
was O
conducted O
to O
trace O
the O
origin O
of O
this O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
from O
England O
, O
Newfoundland O
and O
the O
United O
States O
. O

Microsatellite O
- O
based O
haplotype O
analysis O
was O
undertaken O
to O
explore O
the O
mutationâ€™s O
origin O
in O
colorectal B-Disease
cancer I-Disease
families O
across O
three O
regions O
. O

The O
study O
used O
MSH2 O
- O
linked O
microsatellite O
markers O
to O
analyse O
the O
origin O
of O
the O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
from O
multiple O
geographic O
groups O
. O

Researchers O
performed O
haplotype O
mapping O
using O
MSH2 O
- O
associated O
microsatellite O
markers O
to O
investigate O
mutation O
origins O
in O
colorectal B-Disease
cancer I-Disease
families O
. O

Haplotype O
analysis O
employing O
MSH2 O
- O
linked O
microsatellites O
clarified O
the O
geographical O
origins O
of O
the O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
. O

These O
findings O
point O
to O
a O
founder O
effect O
in O
Newfoundland O
, O
mirroring O
reports O
of O
MLH1 O
mutations O
in O
Finnish O
HNPCC B-Disease
families O
. O

The O
results O
support O
the O
existence O
of O
a O
founder O
effect O
in O
Newfoundland O
analogous O
to O
MLH1 O
- O
associated O
founder O
mutations O
in O
Finnish O
HNPCC B-Disease
families O
. O

The O
data O
indicate O
a O
Newfoundland O
founder O
effect O
comparable O
to O
previously O
described O
MLH1 O
mutations O
in O
Finnish O
HNPCC B-Disease
families O
. O

Researchers O
inferred O
a O
Newfoundland O
founder O
effect O
resembling O
MLH1 O
mutation O
patterns O
seen O
in O
Finnish O
HNPCC B-Disease
families O
. O

The O
study O
suggests O
a O
Newfoundland O
founder O
effect O
parallel O
to O
MLH1 O
mutation O
findings O
in O
Finnish O
HNPCC B-Disease
pedigrees O
. O

For O
both O
sexes O
combined O
, O
penetrance O
at O
age O
60 O
was O
estimated O
for O
all O
cancers B-Disease
and O
for O
colorectal B-Disease
cancer I-Disease
. O

Penetrance O
values O
for O
all O
cancers B-Disease
and O
colorectal B-Disease
cancer I-Disease
at O
age O
60 O
were O
calculated O
for O
males O
and O
females O
collectively O
. O

The O
overall O
penetrances O
of O
all O
cancers B-Disease
and O
of O
colorectal B-Disease
cancer I-Disease
by O
age O
60 O
were O
assessed O
for O
both O
sexes O
. O

The O
study O
estimated O
penetrance O
at O
age O
60 O
for O
all O
cancers B-Disease
and O
specifically O
for O
colorectal B-Disease
cancer I-Disease
in O
both O
sexes O
. O

Researchers O
evaluated O
age O
- O
60 O
penetrance O
values O
for O
all O
cancers B-Disease
and O
colorectal B-Disease
cancer I-Disease
across O
both O
sexes O
. O

The O
risk O
of O
colorectal B-Disease
cancer I-Disease
was O
substantially O
higher O
in O
males O
than O
females O
, O
with O
significant O
differences O
observed O
at O
ages O
50 O
and O
60 O
. O

Males O
exhibited O
a O
markedly O
elevated O
colorectal B-Disease
cancer I-Disease
risk O
compared O
with O
females O
, O
with O
significant O
sex O
- O
based O
differences O
. O

Colorectal B-Disease
cancer I-Disease
risk O
was O
notably O
greater O
in O
males O
, O
showing O
significant O
contrasts O
with O
female O
risk O
estimates O
. O

Sex O
- O
specific O
analysis O
revealed O
a O
significantly O
increased O
colorectal B-Disease
cancer I-Disease
risk O
among O
males O
. O

Colorectal B-Disease
cancer I-Disease
risk O
parameters O
demonstrated O
significantly O
higher O
values O
for O
males O
compared O
with O
females O
. O

Females O
displayed O
elevated O
risks O
of O
endometrial B-Disease
cancer I-Disease
and O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
, O
with O
notable O
penetrance O
at O
ages O
60 O
and O
50 O
, O
respectively O
. O

Significant O
risks O
of O
endometrial B-Disease
cancer I-Disease
and O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
were O
observed O
among O
females O
at O
specific O
ages O
. O

Women O
exhibited O
high O
penetrance O
values O
for O
endometrial B-Disease
cancer I-Disease
by O
age O
60 O
and O
for O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
by O
age O
50 O
. O

Female O
carriers O
showed O
substantial O
risks O
for O
endometrial B-Disease
cancer I-Disease
and O
for O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
at O
designated O
ages O
. O

The O
study O
identified O
elevated O
female O
risks O
for O
both O
endometrial B-Disease
cancer I-Disease
and O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
at O
key O
age O
thresholds O
. O

These O
sex O
- O
based O
differences O
in O
colorectal B-Disease
cancer I-Disease
risk O
affect O
screening O
strategies O
and O
efforts O
to O
identify O
colorectal O
cancer O
susceptibility O
modifiers O
. O

Sex O
- O
specific O
variations O
in O
colorectal B-Disease
cancer I-Disease
risk O
have O
meaningful O
implications O
for O
screening O
and O
discovery O
of O
susceptibility O
modifiers O
. O

The O
observed O
sex O
differences O
in O
colorectal B-Disease
cancer I-Disease
risk O
inform O
screening O
protocols O
and O
modifier O
identification O
studies O
. O

Sex O
- O
related O
risk O
disparities O
in O
colorectal B-Disease
cancer I-Disease
shape O
approaches O
to O
screening O
and O
to O
identifying O
susceptibility O
modifiers O
. O

Intersex O
differences O
in O
colorectal B-Disease
cancer I-Disease
risk O
highlight O
the O
need O
for O
tailored O
screening O
practices O
and O
for O
identifying O
susceptibility O
modifiers O
. O

The O
age O
of O
onset O
in O
Huntington B-Disease
disease I-Disease
is O
influenced O
by O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
in O
a O
sex O
- O
specific O
manner O
. O

Huntington B-Disease
disease I-Disease
age O
of O
onset O
shows O
sex O
- O
specific O
patterns O
linked O
to O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
. O

This O
study O
explores O
sex O
- O
related O
effects O
of O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
on O
Huntington B-Disease
disease I-Disease
age O
of O
onset O
. O

The O
analysis O
identifies O
sex O
- O
specific O
modifiers O
of O
Huntington B-Disease
disease I-Disease
onset O
involving O
apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
. O

Apolipoprotein O
E O
genotype O
and O
normal O
CAG O
repeat O
length O
exert O
sex O
- O
dependent O
effects O
on O
Huntington B-Disease
disease I-Disease
onset O
. O

Age O
of O
onset O
in O
Huntington B-Disease
disease I-Disease
is O
correlated O
with O
expanded O
CAG O
repeat O
length O
in O
the O
HD B-Disease
gene O
. O

Expanded O
CAG O
repeat O
length O
in O
the O
HD B-Disease
gene O
is O
strongly O
associated O
with O
Huntington B-Disease
disease I-Disease
age O
of O
onset O
. O

Huntington B-Disease
disease I-Disease
onset O
is O
influenced O
by O
the O
size O
of O
the O
expanded O
CAG O
repeat O
in O
the O
HD B-Disease
gene O
. O

The O
expanded O
CAG O
repeat O
within O
the O
HD B-Disease
gene O
shows O
a O
clear O
relationship O
with O
Huntington B-Disease
disease I-Disease
age O
of O
onset O
. O

Apolipoprotein O
E O
genotype O
influences O
age O
of O
onset O
in O
Alzheimer B-Disease
disease I-Disease
and O
may O
affect O
onset O
in O
other O
neurological B-Disease
diseases I-Disease
. O

APOE O
genotype O
impacts O
Alzheimer B-Disease
disease I-Disease
onset O
and O
is O
a O
plausible O
modifier O
in O
additional O
neurological B-Disease
diseases I-Disease
. O

The O
APOE O
gene O
affects O
Alzheimer B-Disease
disease I-Disease
age O
of O
onset O
and O
may O
play O
a O
similar O
role O
in O
other O
neurological B-Disease
diseases I-Disease
. O

APOE O
genotype O
shapes O
Alzheimer B-Disease
disease I-Disease
onset O
and O
is O
considered O
a O
candidate O
modifier O
in O
various O
neurological B-Disease
diseases I-Disease
. O

The O
impact O
of O
APOE O
genotype O
on O
Alzheimer B-Disease
disease I-Disease
suggests O
possible O
roles O
in O
onset O
modulation O
across O
other O
neurological B-Disease
diseases I-Disease
. O

APOE O
genotype O
and O
normal O
CAG O
repeat O
length O
were O
measured O
in O
138 O
HD B-Disease
patients O
previously O
assessed O
for O
expanded O
CAG O
repeat O
length O
. O

This O
study O
determined O
APOE O
genotype O
and O
normal O
CAG O
repeat O
counts O
in O
HD B-Disease
patients O
with O
prior O
expanded O
repeat O
analyses O
. O

Researchers O
assessed O
APOE O
genotype O
and O
normal O
CAG O
repeat O
size O
in O
138 O
HD B-Disease
individuals O
already O
evaluated O
for O
expanded O
repeats O
. O

The O
analysis O
included O
APOE O
genotyping O
and O
measurement O
of O
normal O
CAG O
repeat O
length O
in O
previously O
characterised O
HD B-Disease
patients O
. O

The O
study O
evaluated O
APOE O
genotype O
and O
normal O
CAG O
repeat O
length O
in O
138 O
HD B-Disease
patients O
with O
existing O
expanded O
repeat O
data O
. O

